ClinicalTrials.gov
public full text
Public Domain
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
This study was conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled. The primary endpoint is to demonstrate liafensine is superior to placebo in DGM4 positive patients with TRD.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression#886326
- Multiple Ascending Dose Phase 1 Study of ALA-3000#888825
- Effect of Self-administered tDCS in Patients With MDD#1010172
- Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)#879732
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)#889571
Record · ID 889503
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive